CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Move comes amid rising regulatory pressures
Pharma giant targets new standards of care
By cutting pain crises & boosting haemoglobin
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Subscribe To Our Newsletter & Stay Updated
